The Phase III trial (NCT01436968), conducted under a Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA), saw a generally ... and confirms our previous observation of ...
Moreover, aged patients are at highest risk of suffering from chronic diseases; thus, rapid increase in geriatric population is expected to further drive the demand for medical imaging reagents.